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A B S T R A C T
This paper presents a novel poly(dimethylsiloxane) (PDMS) microﬂuidic immunosensor that integrates a
complementary metal-oxide-semiconductor (CMOS) optical detection system for a rapid and highly-sensitive
quantiﬁcation of salivary cortisol. The simple and non-invasive method of saliva sampling provides an
interesting alternative to the blood, allowing a fast sampling at short intervals, relevant for many clinical
diagnostic applications. The developed approach is based on the covalent immobilization of a coating antibody
(Ab), a polyclonal anti-IgG, onto a treated PDMS surface. The coating Ab binds the capture Ab, an IgG speciﬁc
for cortisol, allowing its correct orientation. Horseradish peroxidase (HRP)-labelled cortisol is added to compete
with the cortisol in the sample, for the capture Ab binding sites. The HRP-labelled cortisol, bonded to the
capture Ab, is measured through the HRP enzyme and the tetramethylbenzidine (TMB) substrate reaction. The
cortisol quantiﬁcation is performed by colorimetric detection of HRP-labelled cortisol, through optical
absorption at 450 nm, using a CMOS silicon photodiode as the photodetector. Under the developed optimized
conditions presented here, e.g., microﬂuidic channels geometry, immobilization method and immunoassay
conditions, the immunosensor shows a linear range of detection between 0.01–20 ng/mL, a limit of detection
(LOD) of 18 pg/mL and an analysis time of 35 min, featuring a great potential for point-of-care applications
requiring continuous monitoring of the salivary cortisol levels during a circadian cycle.
1. Introduction
Nowadays, the physical and psychological chronic stress, originated
from stressful daily routine, is known to trigger disorders, such as
depression and cardiovascular diseases (Lederbogen et al., 2011).
Therefore, a great eﬀort is being made to develop tools for stress
monitoring. One of the most important stress biomarkers is the
hormone cortisol (Lucassen et al., 2014). Cortisol levels in the body
ﬂuids follow a circadian cycle, which have maximum levels in the
morning, decreasing during the day and registering a minimum before
sleep (Lucassen et al., 2014; Quax et al., 2013). A common feature of
maladaptive response to chronic stress is the increased cortisol levels in
speciﬁc periods or abnormal circadian cycle. Therefore, it is of utmost
importance to monitor the cortisol concentration in the human body
along the day.
Saliva has emerged as a useful alternative ﬂuid, as compared to
blood, for measuring cortisol concentration. Its main advantage relies
in an easy and non-invasive collection method, which reduces the
stress response and allows a fast sampling at short time intervals,
enabling a continuous monitoring of cortisol levels. Moreover, salivary
cortisol is present in the free state (biologically active), which is the
relevant form for its detection, contrary to what occurs in the blood,
where about 90% of it is bonded to proteins (Gröschl, 2008; Kaushik
et al., 2014). However, salivary cortisol levels, which range between 1
and 8 ng/mL in healthy adults, are up to 100 times smaller than in the
blood, requiring highly sensitive and accurate detection methods
(Stevens et al., 2008; Yamaguchi et al., 2013).
The traditionally analytical methods for measuring the salivary
cortisol levels include high performance liquid chromatography
(HPLC) (Chen et al., 2010), ﬂuorometric assay, radioimmunoassay
(RIA) (Kaushik et al., 2014), ﬂow immunoassay and enzyme linked
immunosorbent assay (ELISA) (Sesay et al., 2013; Tlili et al., 2011).
Although these methods provide high sensitivity, they are expensive,
time and reagent/sample consuming, involve multiple step reaction,
washing processes, and involve the use of radioisotopes, features that
are inappropriate for miniature and portable devices (Kaushik et al.,
2014; Tlili et al., 2011). Aiming the miniaturization of the device,
several antibodies (Ab)-based biosensors (immunosensors) have been
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reported for cortisol detection based on electrochemical (Tlili et al.,
2011) and surface plasmon resonance (SPR) detection techniques
(Stevens et al., 2008). Microﬂuidic devices have emerged as an
interesting alternative to those miniaturization eﬀorts, comprising
advantages such as eﬃciency, automation, portability, analysis time
and reagents/samples reduction, and above all, a reduction of the
overall cost (Bange et al., 2005).
Recently, as an alternative to Ab-based biosensors for cortisol
detection, it has been reported the use of aptamers (single-stranded
DNA or RNA sequences that recognize speciﬁc targets) as an immo-
bilization-free strategy, owing to their simple synthesis and good
selectivity and stability (Wei et al., 2015). Although this new strategy
presents some potential to be used in microﬂuidic applications, the Ab
technology is yet preferred for point-of-care devices since it is well
established, numerous immunoreagents are commercially available for
several analytes and the Ab have a much stronger binding aﬃnity than
aptamers, which means that it is necessary to use more aptamers to do
the same task when compared with Ab (Kedzierski, et al., 2012;
Hasegawa et al., 2016). In this work the development of a microﬂuidic
immunosensor (Ab-based biosensor) fabricated in poly(dimethylsilox-
ane) (PDMS) is described. It integrates optical techniques for a rapid
and highly-sensitive detection and quantiﬁcation of salivary cortisol
concentration (Fig. 1). The use of a PDMS platform features optical
transparency, needed for optical detection; allows fabrication in
nanometer features without the need of cleanroom facilities; and
allows low-cost for prototyping (Pinto et al., 2014). Moreover, although
a paper based microﬂuidic platform could be advantageous due to a
more eﬀective low-cost and simple fabrication (Kakoti, et al., 2015; Li,
et al., 2012; Ren et al., 2013), it seems incompatible with the working
conditions here due to the very low concentration and small size of the
analyte, and the absorbance detection. Usually, a paper-based micro-
ﬂuidic device features limitations regarding the retention or diﬀusion
of the reagents and the sample in the inner highly porous cellulose
matrix (dilution), which can block the internal signal in the detection
zone, leading to an unsatisfactory detection sensitivity (Ren et al.,
2013).
To our knowledge there are no previous reports on a microﬂuidic
immunosensor for salivary cortisol quantiﬁcation that integrates the
immunoassay on a PDMS microﬂuidic die and the optical absorption as
the detection technique. The immunoassay is based on a competitive
assay, due to the low molecular weight and the low concentration of the
cortisol molecule, enabling low detection limit (Bojorge Ramírez et al.,
2009). This competitive assay features an output signal that is inversely
proportional to the cortisol concentrations, which is a required feature
due to the low cortisol concentrations in saliva. This approach renders
this immunosensor an eﬀective device for measuring the salivary
cortisol concentration.
2. Material and methods
2.1. Materials
HRP-labelled cortisol (F-HRP), Hidrocortisone and rabbit anti-
cortisol IgG (capture Ab) were obtained from CosmoBio. The poly-
clonal goat Ab anti-rabbit-IgG (coating Ab),
3,3′,5,5'Tetramethylbenzidine (TMB), aminopropyltriethoxysilane
(APTES), glutaraldehyde (GA), Tween20 and bovine serum albumin
(BSA) were obtained from Sigma-Aldrich. Sylgard 184 silicone elasto-
mer (PDMS) was purchased from Dow Corning and the SU-8 negative
photoresist from MicroChem. All other chemicals were obtained from
Thermo Fisher Scientiﬁc.
Fig. 1. (A) Schematic illustration of the salivary cortisol microﬂuidic immunosensor. (B) PDMS microﬂuidic device with dimensions of: 5 mm for the Y shape inlet length and 45.7 mm
for the serpentine channel length; all the microchannels have a 200 µm width and 100 µm thickness; the outlet microchannel has 500 µm width and 3 mm length; the reaction chamber
is a cylinder shape with a diameter and thickness of 3 mm.
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2.2. Apparatus
The 100 W Plasma Systems ZEPTO from Diener electronic was
used for the PDMS surface modiﬁcation. Absorption spectra were
recorded with a setup that includes a 250 W quartz tungsten halogen
lamp, as light source; a monochromator (Newport 74125); an optical
ﬁber (Newport Standard Grade FS Fiber Optic), used to guide the light
trough the sample and into the photodiodes box; and a picoammeter
(Keithley 487) to measure the photodiode current. A neMESYS Syringe
Pump system with three 5 mL volume syringes individually controlled
by the neMESYS UserInterface was used to control the ﬂow inside the
microchannels.
2.3. Ab immobilization on the PDMS surface
The competitive assay uses the covalent immobilization of the
coating Ab via GA onto APTES-treated PDMS surface (Fig. S1 in the
Supplementary material). For that, the PDMS surface was modiﬁed by
oxygen plasma during 60 s featuring the -Si(OH)x groups (Chuah et al.,
2015). An aqueous solution of 50% v/v APTES in absolute ethanol was
immediately added and incubated during 20 min, which reacts with the
hydroxyl groups on plasma-treated PDMS and produces amine groups
(-NH2). These optimal conditions, especially the APTES concentration
and the incubation time, were studied by ﬂuorescamine assay and
transmittance (Fig. S2 in the Supplementary material). The PDMS
samples were washed with absolute ethanol to remove the APTES
excess and dried with a nitrogen ﬂow. After this, the APTES-treated
PDMS was incubated at 80 °C in a vacuum oven for 2 h. The NH2-
funcionalized PDMS surface was then reactivated using 2.5% of GA in
PBS for 1 h at room temperature (RT) and washed with PBS and dried
with nitrogen ﬂow. Finally, the coating Ab was immobilized on the
PDMS surface by overnight incubation. Atomic force microscopy
(AFM) analyses showed a quite uniform distribution of the coating
Ab on PDMS surface proving the eﬃciency of this immobilization
method (Fig. S3 in the Supplementary material).
2.4. Blocking solution eﬃciency for non-speciﬁc adsorption on PDMS
Despite the success of the coating Ab immobilization onto APTES-
treated PDMS surface, non-speciﬁc proteins can also adsorb to the
surface leading to false positive results. Therefore, a blocking solution
of 0.1% BSA +3% sucrose, prepared in borate buﬀer at pH 7.8, was
added for 4 h at RT. Afterwards the PDMS was washed with PBS-
Tween20 and stored at 4 °C for, at least, 3 weeks until its use. Table S1
in the Supplementary material shows this solution eﬃciency.
2.5. Sensitivity analysis
The calibration curves of the immunoassay (dependence of absor-
bance at 450 nm on HRP-labelled cortisol concentration) were ob-
tained by plotting the absorbance against the logarithm of cortisol
standards concentrations (0–1000 ng/mL) using Origin 8.0. The curve
was ﬁtted using a nonlinear four parameters logistic calibration plot
and deﬁned by (Sesay et al., 2013):
ay = (1 − )





where a and d are the asymptotic maximum and minimum values,
respectively; c is the value at the inﬂection point; b is the slope; y is the
absorbance and x is the logarithm of the cortisol concentration. The
sensitivity of the immunoassay may be deﬁned as the limit of detection
(LOD), which is deﬁned as the smallest concentration of cortisol that is
able to produce a signal that can be distinguished from the signal
obtained in the absence of that analyte (Armbruster and Pry, 2008). To
make a direct comparison between the various calibration curves, the
absorbance data was normalized. This transformation was performed
by the values of %A/A0, where A is the sample absorbance and A0 is
the absorbance at zero concentration.
3. Results and discussion
3.1. Immunoassay optimization for salivary cortisol on PDMS wells
In order to ﬁnd the optimal conditions of the complete immunoas-
say towards high sensitivity with low sample and reagents volumes,
optimization assays were performed with diﬀerent concentrations of
the reagents (coating Ab, capture Ab and HRP-labelled cortisol), as well
as with diverse incubation periods. The optimization was initially
performed in rectangular PDMS wells (4 mm length ×3 mm width
×3 mm height) at RT. Firstly, the measurements were made with no
standard cortisol (0 ng/mL) to obtain the maximum absorbance signal.
In this step several coating Ab concentrations (2 µg/mL, 10 µg/mL and
20 µg/mL) and capture Ab (1:10000, 1:25000, 1:50000, 1:100000,
1:200000; 1:500000, 1:1000000 and 1:2000000) were used, with a
ﬁxed concentration of HRP-labelled cortisol (1:25000). To ﬁnd the
optimal concentration of HRP-labelled cortisol, it was done, simulta-
neously, a study using several HRP-labelled cortisol dilutions (1:10000,
1:25000, 1:50000, 1:100000) where a ﬁxed concentration of coating Ab
(10 µg/mL) and capture Ab (1:50000) were used taking into consid-
eration the previous results of this work.
The optimal concentration extrapolated from our results was 10 µg/
mL for the coating Ab (see Fig. 2A). Despite the absorbance signal of
20 µg/mL being slightly higher, 10 µg/mL was chosen since it provides
almost the same absorbance signal and it allows reagents parsimony.
The optimal dilution of capture Ab and HRP-labelled cortisol were
determined (1:50000 and 1:25000, respectively), with absorbance
values of 1.0, as shown in Fig. 2A and B, leading to stable results.
To determine the best reaction time of the capture Ab with HRP-
labelled cortisol and standard cortisol, 10 µL of each of these reagents
were incubated in the PDMS wells, pre-functionalized with coating
capture Ab for 30 min, 1 h, 2 h, and 3 h. Then, the PDMS wells were
washed with PBS-Tween20 and 20 µL of TMB were added for 10 min.
Finally, 10 µL of stop solution was added and the absorbance measured
at 450 nm. The incubation time was deﬁned as 1 h (Fig. 2C) since the
experimental results showed a stabilized absorbance maximum value.
3.2. Sensitivity of the salivary cortisol analysis on PDMS wells
The assays for obtaining the calibration curve (Fig. 2D) were
performed in the reported Ab immobilization on the PDMS wells,
which have previously been pre-functionalized with coating Ab at a
concentration of 10 µg/mL. In these wells it was added: 10 µL of
capture Ab diluted in borate buﬀer with the ratio 1:50000; 10 µL of
HRP-labelled cortisol diluted in borate buﬀer with the ratio 1:25000;
and 10 µL of standard cortisol at diﬀerent concentrations, from 0.1 to
1000 ng/mL Then, the PDMS wells mixtures were stirred, manually,
during 1 min to promote the mixture of the three reagents and
incubated for 1 h. After this time, the PDMS wells were washed with
30 µL of PBS-Tween20 and 20 µL of TMB solution and incubated at RT
for 10 min. Finally, 10 µL of sulfuric acid (2 M) was added to stop the
reaction and after that the optical absorption were measured. It was
used a low concentration of sulfuric acid (2 M) and short interaction
time within microﬂuidic device and thus, no inconvenience eﬀect was
observed in the PDMS. The obtained calibration curve for the
optimized immunoassay showed a LOD of 10 pg/mL and a working
range of 0.01–20 ng/mL (Fig. 2D). These results lead to the imple-
mentation of the microﬂuidic immunoassay.
3.3. Selectivity of the salivary cortisol analysis on PDMS wells
In order to verify the speciﬁcity of the immunoassay, e.g., if any
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reagents (buﬀer, blocking solution, coating and capture Ab) interfered
in the previous absorbance measurements leading to incorrect cortisol
concentration results, it was performed absorbance measurements, at
450 nm, considering these reagents alone. The experimental results,
presented in Fig. 2E, show that there was not signiﬁcant interference
due to the extremely low absorbance obtained for those reagents in
comparison with the test that includes capture Ab and HRP-labelled
cortisol, where it is observed the maximum absorbance.
3.4. Microﬂuidic device design and fabrication
After optimizing the immunoassay on PDMS wells, the microﬂuidic
device was designed. It must include two inlets and a channel to mix
the ﬂuids before reaching the reaction chamber. The best microchan-
nels geometry and length for an eﬃcient mixing were evaluated
through ﬁnite elements numerical simulations using COMSOL
Multiphysics software. This study aimed to determine if the channels
allowed the complete ﬂuids mixture before reaching the reaction
Fig. 2. (A) Optimization of the coating and capture Ab concentration using a dilution of HRP-labelled cortisol of 25000 (v/v). (B) Optimization of the HRP-labelled cortisol dilution. (C)
Optical absorption of HRP-labelled cortisol for diﬀerent reaction times of capture Ab with HRP-labelled cortisol and cortisol standard. (D) Calibration curve obtained with the optimized
immunoassay in the PDMS wells. (E) Experimental controls of the competitive immunoassay developed for salivary cortisol in the PDMS wells. Error bars indicate the calculated
standard deviation (n=3) and maximum standard deviations of (A) 5.1%, (B) 4.7%, (C) 3.6% and (D) 3.2% were obtained.
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chamber. Thus, two diﬀerent geometries have been designed and
simulated: one Y-shaped straight channel with 20 mm length and
200 µm width, as detailed in Tables S2 and S3 in the Supplementary
material. The simulation results (Fig. S4, Supplementary material)
demonstrated that the serpentine microchannels are the most suitable
option for the desired application. This geometry allows a longest ﬂow
length, essential to assure the complete mixture of ﬂuids by convection-
diﬀusion phenomena, maintaining the small dimensions of the micro-
ﬂuidic device.
The fabrication of the PDMS microﬂuidic device was performed by
a soft lithography technique using a SU-8 mold for the microﬂuidic
channel and by micromachining using an acrylic mold for the reaction
chamber that was polished oﬀ to remove the roughness. Details of the
SU-8 molds processing steps can be found in Pinto et al. (2014). The
PDMS solution, composed of 1/10%wt of base/curing agent, was
poured over the molds and cured at 80 °C during 2 h. Holes were then
punched to provide access to the inlets and to the outlets in the desired
location with a syringe tip. In the PDMS reaction chamber it is
performed all the optimized immobilization process described in
Sections 2.3 and 2.4. Then, it is aligned with the channels slice and
closed via O2 plasma. The PDMS serpentine channel for the micro-
ﬂuidic immunosensor application is shown in Fig. 1B. It was designed
to be disposable.
3.5. Optical detection of salivary cortisol in the microﬂuidic device
The microﬂuidic immunosensor was tested using an experimental
setup that comprises three subsystems: the microﬂuidic die; a ﬂuidic
pumping control (Nemesys Syringe Pump); and a spectrophotometric
system for optical absorption measurements. The immunoassay inside
the microﬂuidic device was performed pumping 5 µL of capture Ab
with a ﬂow rate of 2 µL/min in one of the inlets and in the other inlet it
was introduced 10 µL of HRP-labelled cortisol and cortisol standard
(5 µL of each) with a ﬂow rate of 4 µL/min. These last two solutions
were incubated in the microﬂuidic device reaction chamber during
20 min. It should be noticed that, using the same reagents, the
incubation time in the PDMS wells was 1 h. This time reduction was
due to the serpentine microchannel geometry, to the increase of the
contact area in the microchannel interior, as well as to the deduced size
of the reaction chamber. Then, the washing solution of PBS-Tween20
was pumped with a ﬂow rate of 4 µL/min during 1 min. The third inlet
that leads to the reaction chamber was used to introduce a 10 µL of
TMB that was incubated for 10 min. After that, this mixture produced a
blue color inside the reaction chamber (Fig. S5a in the Supplementary
material). Then, it was introduced 5 µL of stop solution, which
produced a yellow color (Fig. S5b in the Supplementary material)
and the optical absorption was measured at 450 nm, using an on-chip
silicon p-n junction photodiode with an active area of 1×1 mm2,
positioned below the reaction chamber. The on-chip immunosensor
calibration curve showed a LOD of 18 pg/mL and a working range of
0.01–20 ng/mL (Fig. 3A).
Notably, the developed sensor can oﬀer a solution for the detection
of cortisol with a signiﬁcant decrease of the reagents consumption and
time (see Fig. 3B), when compared with the conventional gold-
standard methods. Furthermore, the microﬂuidic immunosensor en-
ables cortisol detection down to 18 pg/mL within about 35 min
analysis time.
These results show the PDMS viability as material for the micro-
ﬂuidic device fabrication, enhancing its main advantages (high optical
transparency, easy and stable Ab immobilization on the PDMS sur-
face), when compared to paper-based microﬂuidic devices, which
would have limitations regarding the retention of the analyte, especially
when are involved low molecular weight and low cortisol concentra-
tion, as in the proposed immunoassay. The presented results also prove
the viability of this immunosensor for cortisol quantiﬁcation with low
LOD, using commercial available immunoreagents and through well-
established methods (Ab-based), when compared to other approaches,
e.g. aptamers. Therefore, these results suggest that the developed
microﬂuidic device is promising for quantiﬁcation of salivary cortisol
levels (normal values between 1–8 ng/mL).
4. Conclusions
This paper reports the development of a novel PDMS microﬂuidic
immunosensor for the determination of salivary cortisol concentration
using optical absorption integrated in CMOS. It oﬀers distinct advan-
tages, when compared with the gold-standard methods: (1) decreased
reagents consumption (5–20 µL) and analysis time (35 min); (2) low-
cost and easy fabrication; (3) LOD of 18 pg/mL; (4) linear detection
range between 0.01–20 ng/mL; (5) point-of-care applications for
monitoring salivary cortisol secretion in a circadian cycle.
In the future, the immunosensor can be fabricated with a miniatur-
ized and reusable pumping, mixing and control system that includes
the actuation components (e.g. piezoelectric micropumps) integrated in
the electronic systems (Rife et al., 2000; Catarino et al., 2014, 2016).
To do so one can make use of commercially available compact and
lightweight systems, such as micro piezo pumps, speciﬁcally designed
for microﬂuidics applications.
Fig. 3. (A) The calibration curve obtained in the microﬂuidic immunosensor using the on-chip photodiode. Error bars indicate the calculated standard deviation (n=3) and a maximum
standard deviation of 4.8% was obtained. (B) Analytical performance of the microﬂuidic immunosensor in comparison with the conventional gold-standard ELISA method.
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